Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
Tanya E KeenanTianyu LiTuulia ValliusJennifer L GuerrieroNabihah TayobBose KochupurakkalJanae A DavisRicardo PastorelloRie K TaharaLeilani AndersonJake ConwayMeng X HeErin ShannonRobert E GodinPeter Karl SorgerAlan D' AndreaBeth A OvermoyerEric P WinerElizabeth A MittendorfEliezer M Van AllenGeoffrey I ShapiroSara M TolaneyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Among patients with mTNBC treated with 0-1 prior lines, adavosertib combined with cisplatin missed the prespecified ORR cutoff of >30%. The finding of immune-infiltrated tumors in patients with clinical benefit warrants validation.
Keyphrases